In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Polly Murphy Biography and Net Worth

Director of Atea Pharmaceuticals

Polly A. Murphy is on the Board of Directors at Atea Pharmaceuticals. Polly is also the Chief Business Officer at UroGen Pharma.

How do I contact Polly A. Murphy?: The corporate mailing address for Dr. Murphy and other Atea Pharmaceuticals executives is , , . Atea Pharmaceuticals can also be reached via phone at 857-284-8891 and via email at [email protected]. Learn More on Polly A. Murphy's contact information.
Has Polly A. Murphy been buying or selling shares of Atea Pharmaceuticals?: Polly A. Murphy has not been actively trading shares of Atea Pharmaceuticals during the past quarter. Most recently, on Monday, December 20th, Polly A. Murphy bought 12,000 shares of Atea Pharmaceuticals stock. The stock was acquired at an average cost of $8.57 per share, with a total value of $102,840.00. Learn More on Polly A. Murphy's trading history.
Are insiders buying or selling shares of Atea Pharmaceuticals?: During the last twelve months, insiders at the sold shares 7 times. They sold a total of 139,562 shares worth more than $537,929.91. The most recent insider tranaction occured on September, 19th when CEO Jean-Pierre Sommadossi sold 1,841 shares worth more than $7,364.00. Insiders at Atea Pharmaceuticals own 17.8% of the company. Learn More about insider trades at Atea Pharmaceuticals.
Information on this page was last updated on 9/19/2024.

Polly A. Murphy Insider Trading History at Atea Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/20/2021	Buy	12,000	$8.57	$102,840.00

Polly A. Murphy Buying and Selling Activity at Atea Pharmaceuticals

Atea Pharmaceuticals Company Overview

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $3.22

$3.18

$3.35

50 Day Range

MA: $3.51

$3.22

$4.02

2 Week Range

Now: $3.22

$2.77

$4.60

Volume

313,823 shs

Average Volume

167,651 shs

Market Capitalization

$271.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.17

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad